

CURRICULUM VITAE OF ALFRED E. STAUBUS

ALFRED E. STAUBUS
1015 Kenway Court
Columbus, Ohio 43220
(614) 451-1406 (Phone)
(614) 451-1407 (FAX)

PERSONAL DATA:

Birthdate - November 20, 1947
Birthplace - San Jose, California
Married - Wife - Angela (Palazzolo), BA Degree, UC Berkeley
- Children - (1) Daniel E. Staubus

EDUCATION:

Cabrillo College, Aptos, California, 1965-1967
Major area of study - Pre-Pharmacy - Degree: Assoc. Sci.

University of California, San Francisco, 1967-1971
School of Pharmacy - Degree: Pharm.D.; Major: Clinical Pharmacy

University of California, San Francisco, 1970-1974
Graduate Division - Department of Pharmaceutical Chemistry
Degree: Ph.D. (Pharmaceutical Chemistry);
Ph.D. Minors: Pharmacology and Radiology
Major Research Area: The Pharmacokinetics of Liver
Clearance and Biliary Excretion
Major Professor: Sidney Riegelman, Ph.D.

Intoxilyzer 5000 Operator's Course, April 9-12, 1997
Certificate of Completion and Competency, Marietta, GA.

BAC DataMaster Training Course, June 16-18, 1997
National Patent Analytical Systems, Inc., Mansfield, OH

Intoxilyzer 8000 Breath Alcohol Technician (BAT) Training Course,
February 26, 2005, in conformity with 49 CFR part 40 training and certification

Intoximeter EC/IR II Breath Alcohol Technician (BAT) Training Course,
October 6, 2008, and Intoximeters EC/IR BAT Instructor Training Course,
October 7-8, 2008, St. Louis, MO

AWARDS:

Recipient of University of California University Scholarship, 1968

Recipient of University of California, President's Undergraduate Research
Fellowship, 1970

Recipient of the American Foundation for Pharmaceutical Education, Graduate
Fellowship, 1971-1974

Recipient of the 1973 University of California, San Francisco Chancellor's Award
for Public Service in recognition of "dedication, initiative and innovative
contributions to student health care on the San Francisco campus."

MAJOR RESEARCH INTEREST:

Clinical/Research Applications of Biopharmaceutics and Pharmacokinetics;
Forensic Pharmacokinetics/Toxicology

RESEARCH AND PROFESSIONAL EXPERIENCE:

- 2004 - present Associate Professor Emeritus in the College of Pharmacy
(Pharmaceutics), The Ohio State University
- 1995 - present President, A & A Consultants, Inc.
- 1980 - 2004 Associate Professor in the College of Pharmacy, The Ohio State
University, Division of Pharmaceutics.
Research areas includes pharmacokinetics of
Phase I-II anticancer agents, alcohol and radio-contrast
agents with special emphasis on Michaelis-Menten
pharmacokinetic behavior in relationship to liver function.
- 1979 - 1997 Director/Co-Director/Associate of the Ohio State University
Comprehensive Cancer Center's Clinical Pharmacology
(Pharmacokinetics) Unit.
- 1993-1994 Director of Forensic Toxicology, University
Reference Laboratories, Inc., 1214 Kinnear Road,
Columbus, Ohio 43212.
- 1974-1980 Assistant Professor in the College of Pharmacy,
The Ohio State University, Division of
Pharmaceutics and Pharmaceutical Chemistry.
- 1970-1974 Graduate Studies Graduate Division, University of
California Training in Biopharmaceutics and
Pharmacokinetics. Thesis Title: Fundamentals of
Saturation Kinetics Application to Iopanoic Acid in Dog.
Worked closely with clinical/research radiology.
Degree obtained: Ph.D. (Pharm. Chem.)
Ph.D. minors: Pharmacology and Radiology.
- 1967-1971 Professional Studies, School of Pharmacy,
University of California; Training in Clinical Pharmacy
Degree obtained: Doctor of Pharmacy.

MEMBERSHIPS IN PROFESSIONAL AND SCIENTIFIC SOCIETIES:

American Academy of Forensic Sciences, Toxicology Section
Society for Scientific Detection of Crime (Past President)
American Chemical Society
American Association for Cancer Research
Rho Chi
Listed in the 14th Edition of American Men and Women in Science.
Formerly on the Editorial Staff of the Journal of Investigative Radiology.

PUBLICATIONS:

1. "The Choleric Action of Sodium Tyropanoate (Bilopaque Sodium) in the Dog." Nelson, J. A., Staubus, A. E. and Ambert, J. R., Investigative Radiology, 9, 438-443, 1974.
2. "Fundamentals of Saturation Kinetics - Application to Iopanoic Acid in the Dog." Staubus, A. E., Dissertation Abstracts International, 35, 4850-B, 1975.
3. "Saturation Kinetics of Iopanoate in the Dog." Nelson, J. A., Staubus, A. E. and Riegelman, S., Investigative Radiology, 10, 371-377 (1975).
4. "Tetracycline Bioavailability Monograph." Sokoloski, T. D. and Staubus, A. E., J. of APhA., NS15, 709-712 (1975).
5. "Saturation Kinetics of Iopanoate in Dogs with an Intact Enterohepatic Circulation: Before and After Phenobarbital Induction." Herzog, R. J., Nelson, J. A. and Staubus, A. E., Investigative Radiology, 11, 32-36, (1976).
6. Letter: "Biliary and Urinary Iopanoic Acid Excretion." Nelson, J. A. and Staubus, A. E., Investigative Radiology, 11, 63-64 (1976).
7. "Propoxyphene Bioavailability Monograph." Poust, R. I., Jaffe, J. M., Lesko, L. J. Shangraw, R. F., and Staubus, A. E., J. of APhA., NS16, 97-100 (1976).
8. "Naltrexone Pharmacokinetics: Evaluation of a Sustained Naltrexone Delivery System." Reuning, R. H., Malspeis, L., Staubus, A. E., Bathala, M. S. and Ludden, T. M., in Critical Concerns in the Field of Drug Abuse, Dekker, New York, 1978, pp. 1199-1205.
9. "Saturation Kinetics of Iocetamic Acid: Evaluation of Indirect Pharmacokinetic Techniques and Comparison with Iopanoic Acid." Staubus, A., Berk, R., Loeb, P. and Barnhart, J., Investigative Radiology, 13, 85-92 (1978).
10. "Oral Cytembena Absorption and Phase I-II Studies." Neidhart, J. A., Staubus, A., Young, D., Balcerzak, S. and Malspeis, L., Cancer Treatment Reports, 62, 401-403 (1978).
11. "Plasma Naltrexone Kinetics After Intravenous Bolus in Dog and Monkey." R. H. Reuning, V. K. Batra, T. M. Ludden, M-Y. Jao, B. R. Morrison, D. A. McCarthy, S. E. Harrigan, S. B. Ashcraft, R. A. Sams, M. A. Bathala, A. E. Staubus and L. Malspeis, J. Pharm. Sci., 68, 411-416 (1979).
12. "Elementary Pharmacokinetics, Part I: Theoretical Aspects of Elementary Pharmacokinetics." Staubus, A. E., J. Postgrad. Pharmacy (Hospital Edition) 1, 34-39 (1979).
13. "Elementary Pharmacokinetics, Part IV: Dosage Individualization of a Michaelis-Menten Eliminated Drug, Phenytoin." Staubus, A. E., J. Postgrad. Pharmacy (Hospital Edition) 1, (1979).
14. "Urinary Iodine Excretion Rates Following Intrathecal Injections of Iodinated Organic Carbonates." Staubus, A. E., Newton, B. N., Klein, L. C., Weinrib, A. B. and Kunz, A. L., J. Pharm. Sci., 68, 1438-1143 (1979).

15. "Clinical Toxicities of Imidazolo-Pyrazolo (NSC-51143) with Relevant Pharmacokinetic Parameters." Neidhart, J. A., Staubus, A. E., Young, D., King, G. W., and Malspeis, L., Cancer Treatment Reports, 64, 252 (1980).
16. "Pharmacokinetics: An Analysis of the Method." Staubus, A. E., Investigative Radiology, 15, 591 (1980).
17. "Pharmacokinetic Quantitation of Naltrexone Release from Several Sustained-Release Delivery Systems." Reuning, R. H., Liao, S. H. T., and Staubus, A. E., Naltrexone Research Monograph 28, R. E. Willette and G. Barnett, eds, National Institute on Drug Abuse, 1980.
18. "Optimal Perfusion Rate Determined for In Situ Intestinal Absorption Studies in Rats." Savina, P. M., Staubus, A. E., Gaginella, T. S., and Smith, D. F., J. Pharm. Sci., 70, 239-243 (1981).
19. "Fluorescent Excitation Analysis of Nonradioactive Xenon: A Non-invasive Technique for Estimating Splanchnic Perfusion." Nelson, J. A., Staubus, A. E., Weinrib, A. B., Westenskow, D. R., and Rikkers, Layton F. Chapter 25. Measurement of Blood Flow - Applications to the Splanchnic Circulation. Edited by D. Neil Granger, Gregory B. Bulkley, Waverly Press, 1981.
20. "Pharmacokinetic Quantitation of Naltrexone Sustained Release from a Copolymer Delivery System." Reuning, R. H., Liao, S. H. T., Staubus, A. E., Ashcraft, S. B., Downs, D. A., Harrigan, S. E., Wiley, J. N. and Wise, D. L. J. Pharmacokinetics and Biopharm., 11(4), 369 (1983).
21. "Pharmacokinetics of 5,6-Dihydro-5-Azacytidine (NSC 264880) in the Foxhound." Louis Malspeis, Haiyung Cheng, A. E. Staubus, J. Investigational New Drugs, 1, 47-58 (1983).
22. "Pharmacokinetics of Indoprofen (4-[1,3-Dihydro-1-oxo-2H-isoindo1-2-yl]- α -Methylbenzene acetic acid) in the Rat: Influence of Exteriorization of the Bile Duct and Explanation of Selective Toxicity in the Rat." R. A. Kershaw, A. Staubus, D. E. Sharp, J. Bianchine and N. Gerber. Proc. West. Pharmacol. Soc. 26: 397-401 (1983).
23. "Concept of Clearance and Mean Residence Time in Michaelis-Menten Elimination Systems." Alfred E. Staubus and D. F. Smith, The Sidney Riegelman Memorial Symposium, Pharmacokinetics: A Modern View, April 22-24, 1982, San Francisco, California, p. 411, Plenum Press, 1984.
24. "Clinical Pharmacokinetics of 2'-Deoxycoformycin." Louis Malspeis, Arnold B. Weinrib, Alfred E. Staubus, Michael R. Grever, Stanley P. Balcerzak, and James E. Neidhart. Cancer Treatment Symposia, 2, 7-15 (1984).
25. "An Enzymatic Kinetic Method for the Determination of 2'-Deoxycoformycin in Biological Fluids." Alfred E. Staubus, Arnold B. Weinrib and Louis Malspeis. Biochemical Pharmacology, 33, 1633-1637 (1984).

26. "The Disposition and Metabolism of Tiazofurin in Rodents, Rabbits and Dogs." Susan T. Arnold, Hiremagalur, N. Jayaram, Gregory R. Harper, Charles L. Litterst, Louis Malspeis, John J. V. DeSouza, Alfred E. Staubus, Gurpreet S. Ahluwalia, Yvonne A. Wilson, David A. Cooney, and David G. Johns. Drug Metabolism and Disposition, 12, 165-173 (1984).
27. "Combination of 2'-Deoxycofomycin and Vidarabine in Advanced Malignancy - Clinical and Biochemical Observations." Michael R. Grever, Louis Malspeis, Eric H. Kraut, Henry E. Wilson, Alfred E. Staubus, Mary Sue Coleman, Stanley P. Balcerzak. Cancer Treatment Symposia, 2, 97-103 (1984).
28. "The Use of Deuterium Oxide for the Prediction of Body Composition in Live Dairy Cattle." Willie O. Odwongo, H. R. Conrad and A. E. Staubus, J. Nutri., 114, 2127-2137 (1984).
29. "Injection of Cells and Monoclonal Antibodies into Mice: Comparison of Tail Vein and Retroorbital Routes (41955)." John E. Price, Rolf F. Barth, Carol W. Johnson, and Alfred E. Staubus, Proceedings of the Society for Experimental Biology and Medicine, 177, 347-353 (1984).
30. "Measurement of Water Kinetics with Deuterium Oxide in Lactating Dairy Cows." Willie D. Odwongo, H. R. Conrad, A. E. Staubus and J. H. Harrison, J. Dairy Sci., 68, 1155-1164 (1985).
31. "Disposition of 8-Methoxypsoralen in the Rat: Methodology for Measurement, Dose-Dependent Pharmacokinetics, Tissue Distribution and Identification of Metabolites." Dennis C. Mays, Sharon L. Rogers, Robert C. Guiler, Dale E. Sharp, Stephen G. Hecht, Alfred E. Staubus and Nicholas Gerber, J. Pharm. and Exp. Ther., 236, No. 2, 364-373 (1986).
32. "Parenteral Nutrition: Short Term Effects on Hepatic Clearance of Sodium Taurocholate and Indocyanine Green." Fabri, P. J., Deutsch, S., Gower, W., Jr., Mirtallo, J. M., Staubus, A. E., Love, J. E., Jr., Clin. Biochem. 20(1), 57-60 (1987).
33. "Limited Sampling Models for Amonafide (NSC 308847) Pharmacokinetics." Mark J. Ratain, Alfred E. Staubus, Richard L. Schilsky, and Louis Malspeis. Cancer Res., 38, 4127-4130 (1988).
34. "A Phase I Clinical Investigation of 9- β -D-Arabino-furanosyl-2-Fluoroadenine 5'-Monophosphate (Fludarabine Phosphate) by a Loading Dose and Continuous Infusion Schedule." Jane M. Leiby, Michael R. Grever, Alfred E. Staubus, James A. Neidhart, and Louis Malspeis. J. of the National Cancer Institute, 80, 447 (1988).
35. "An Area Function Method for Estimating the Apparent Absorption Rate Constant." H. Cheng, A. E. Staubus, and L. Shum, Pharm. Res., 5, 57 (1988).
36. "Pharmacokinetic Studies of DISIDA Disposition, I, Animal Studies." I. A. Fraser, P. Shaffer, J. Love, A. E. Staubus, G. Hinkle, J. Olsen, L. C. Carey, P. J. Fabri, and E. C. Ellison. Eur. J. Nucl. Med., 14, 431 (1988).

37. "Pharmacokinetic Studies of DISIDA Disposition, II, Clinical Studies." J. E. Love, P. Shaffer, I. A. Fraser, A. E. Staubus, J. A. Lott, G. Hinkle, L. C. Carey, E. C. Ellison and P. J. Fabri. Eur. J. Nucl. Med., 14, 436 (1988).
38. "Preclinical Studies on Boron Neutron Capture Therapy." Rolf F. Barth, Albert H. Soloway, Fazlul Alam, Nancy R. Clendenon, Thomas E. Blue, Naoki Mafune, Joseph H. Goodman, Wanda Gordon, Bhaskar Bapat, Dianne M. Adams, Alfred E. Staubus, Melvin J. Moeschberger, Reinhard Gahbauer, Allan J. Yates, Carl P. Boesel, Timothy F. Mengers, James F. Curran, Chris K. Wang, George E. Makroglou, Jone-Jiun Tzeng and Ralph G. Fairchild, in Clinical Aspects of Neutron Capture Therapy, eds. R. G. Fairchild, V. Bond and A. Woodhead. Plenum Press, New York, 1989.
39. "DISIDA Kinetics Measure Liver Function in Dogs." I. A. Fraser, P. Shaffer, A. E. Staubus, S. Tuttle, L. C. Carey, and E. C. Ellison. Nucl. Med. Commun., 10(6), 435-447 (1989).
40. "Enhanced Survival in a Rat Glioma Model Following BNCT." N. R. Clendenon, R. F. Barth, J. H. Goodman, A. E. Staubus, W. A. Gordon, M. L. Moeschberger, F. Alam, A. H. Soloway, R. G. Fairchild, D. N. Slatkin, et. al. Strahlenther. Onkol., 165(2-3), 222-225 (1989)
41. "Boron Neutron Capture Therapy of a Rat Glioma." Nancy R. Clendenon, Rolf E. Barth, Wanda A. Gordon, Joseph H. Goodman, Fazlul Alam, Alfred E. Staubus, Carl P. Boesel, Allan J. Yates, Melvin L. Moeschberger, Ralph G. Fairchild and John A. Kalef-Ezra. Neurosurgery, 26, 47-55 (1990).
42. "Pharmacokinetics of 2-F-ara-A (9- β -D-Arabinofuranosyl-2-fluoroadenine) in Cancer Patients During the Phase I Clinical Investigation of Fludarabine Phosphate." Louis Malspeis, Michael R. Grever, Alfred E. Staubus, and Donn Young. Seminars in Oncology, 17(5), Suppl. 8, 18-32(1990).
43. "Pharmacokinetics and Tissue Distribution of Borono-phenylalanine Following Intraperitoneal Injection in Nude Rats with Intracerebral Melanoma", Alfred E. Staubus, Khalid Matalaka, Rolf F. Barth, and Michael Q. Bailey, in Advances in Neutron Capture Therapy, edited by Albert H. Soloway, Rolf F. Barth, and David E. Carpenter, Plenum Press, New York, 1993.
44. "Treatment of Intracerebral Malignant Melanoma Using a Rat Model and L-Boronophenylalanine as the Capture Agent", M.Q. Bailey, K.A. Matalaka, R.F. Barth, J.A. Coderre, A.H. Soloway, J.H. Goodman, A.E. Staubus, and E.K. Rofstad, in Advances in Neutron Capture Therapy, edited by Albert H. Soloway, Rolf F. Barth, and David E. Carpenter, Plenum Press, New York, 1993.
45. "Boron Neutron Capture Therapy (BNCT) of F98 Glioma Bearing Rats Using Boronophenylalanine (BPA) as a Capture Agent", Khalid A. Matalaka, Rolf F. Barth, Alfred E. Staubus, Melvin Moeschberger, and Jeffrey A. Coderre, in Advances in Neutron Capture Therapy, edited by Albert H. Soloway, Rolf F. Barth, and David E. Carpenter, Plenum Press, New York, 1993.

46. "Boron Neutron Capture Therapy of Intracerebral Melanoma Using Boronophenylalanine as a Capture Agent", Khalid Z. Matalka, Michael Q. Bailey, Rolf F. Barth, Alfred E. Staubus, Albert H. Soloway, Melvin L. Moeschberger, Jeffrey A. Coderre, and Einar K. Rofstad. Cancer Research, 53, 3308- 3313 (1993).
47. "Neutron Capture Therapy of a Rat Glioma Using Boronophenylalanine as a Capture Agent", Khalid A. Matalka, Rolf F. Barth, Alfred E. Staubus, Melvin L. Moeschberger and Jeffrey A. Coderre, Radiation Research, 137, 44-51 (1994).
48. "Bioconcentration of 5,5',6 - Trichlorobiphenyl and Pentachlorophenol in the Midge, Chironomus riparius, as Measured by a Pharmacokinetic Model", M.J. Lydy, W.L. Hayton, A.E. Staubus, and S.W. Fisher. Arch. Environ. Contam. Toxicol., 26, 251-256 (1994).
49. "Analysis of Topoisomerase I/DNA Complexes in Patients Administered Topotecan", D. Subramanian, E. Kraut, A. Staubus, D.C. Young and M.T. Muller. Cancer Research, 55, 2097-2103 (1995).
50. "Dietary Uptake Efficiency of HCBP in Channel Catfish: The Effect of Fish Contaminant Body Burden", H. Dabrowska, S.W. Fisher, K. Dabrowski and A.E. Staubus. Environ. Toxicol. Chem., 15, 746-749 (1996).
51. "Determination of the Efficacy of Topical Oral Pilocarpine for Postirradiation Xerostomia in Patients With Head and Neck Carcinoma", D.D. Hamlar, D.E. Schuller, R.A. Gahbauer, R.A. Buerki, A.E. Staubus, J. Hall, J.S. Altman, D.J. Elzinga, and M.R. Martin. Laryngoscope, 106, 972-976 (1996).
52. "Peritoneal Carcinomatosis and Radioimmunoguided Surgery", S. Schneebaum, M.W. Arnold, A.E. Staubus, and E.W. Martin. Cancer Treatment & Research, 82, 193-209 (1996).
53. "Intraperitoneal Hyperthermic Perfusion with Mitomycin C for Colorectal Cancer with Peritoneal Metastases", S. Schneebaum, M.W. Arnold, A.E. Staubus, D.C. Young, D. Dumond, and E.W. Martin, Jr. Annals of Surgical Oncology, 3, 44-50 (1996).
54. "Phase II Trial of Topotecan in Malignant Melanoma", E.H. Kraut, M.J. Walker, A. Staubus, D. Gochmour, and S.P. Balcerzak. Cancer Investigation, 15, 318-320 (1997).
55. "Dietary Uptake Efficiency of 2,2',4,4',5,5'-Hexachlorobiphenyl in Yellow perch and Rainbow Trout: Role of dietary and Body Lipids", H. Dabrowska, S.W. Fisher, K. Dabrowski, and A.E. Staubus. Environmental Toxicology and Chemistry, 18, 935-945 (1999).
56. "Boron Neutron Capture Therapy of Brain Tumors: Biodistribution, Pharmacokinetics, and Radiation Dosimetry of Sodium Borocaptate in Patients with Gliomas", J.H. Goodman, W. Yang, R.F. Barth, Z. Gao, C.P. Boesel, A.E. Staubus, N. Gupta, R.A. Gahbauer, A.H. Soloway, D.E. Carpenter, B.J. Albertson, W.F. Bauer, M.Z. Zhang, and C.C. Wang. Neurosurgery, 47, 608-622 (2000).

57. "High-Flux Hemodialysis without Hemoperfusion is Effective in Acute Valproic Acid Overdose", S.L. Kane, M. Constantiner, A.E. Staubus, C.D. Meinecke, and J.R. Sedor. The Annals of Pharmacotherapy, 34, 1146-1151 (2000).
58. "Boron Neutron Capture Therapy of Brain Tumors: Investigation of Urinary Metabolites and Oxidation Products of Sodium Borocaptate by Electrospray Ionization Mass Spectrometry", C.R. Gibson, A.E. Staubus, R.F. Barth, W. Yang, N.M. Kleinholz, R.B. Jones, K. Green-Church, W. Tjarks, and A.H. Soloway. Drug Metabolism and Disposition, 29, 1588-1598 (2001).
59. "Electrospray Ionization Mass Spectrometry Coupled To Reversed-Phase Ion-Pair High-Performance Liquid Chromatography for Quantitation of Sodium Borocaptate and Application to Pharmacokinetic Analysis", Christopher R. Gibson, Alfred E. Staubus, Rolf F. Barth, Weilian Yang, Nan M. Kleinholz, R. Benjamin Jones, Kari B. Green-Church, Werner Tjarks, and Albert H. Soloway. Anal. Chem., 74, 2394-2399 (2002).
60. "Pharmacokinetics of Sodium Borocaptate: A Critical Assessment of Dosing Paradigms for Boron Neutron Capture Therapy:", Christopher R. Gibson, Alfred E. Staubus, Rolf F. Barth, Weilian Yang, Amy K. Ferketich, and Melvin M. Moeschberger. Journal of Neuro-Oncology, 62, 157-169 (2003).

BOOK CHAPTERS

1. "Breath Testing Science", Victor W. Carmody and Alfred E. Staubus, pages 223-233, in *Understanding DUI Scientific Evidence*, 2nd Edition, 2009 Thomson Reuters/Aspatore.
2. "Evidential Breath-Alcohol Testing Machines", Victor W. Carmody and Alfred E. Staubus, pages 235-282, in *Understanding DUI Scientific Evidence*, 2nd Edition, 2009 Thomson Reuters/Aspatore.
3. "Forensic Toxicology of Urine- and Blood-Alcohol Levels", Alfred E. Staubus, and Robert J. Belloto, Jr., pages 257-267, in *Understanding DUI Scientific Evidence*, 2010 Edition, Thomson Reuters/Aspatore.
4. "The Intoximeter EC/IR II Breath Alcohol Testing Machine", Alfred E. Staubus, pages 411-430, in *Understanding DUI Scientific Evidence*, 2011 Edition, Thomson Reuters/Aspatore.
5. "What is Fifty Pounds Overweight?", Alfred E. Staubus and Jon J. Saia, pages 459-468, in *Understanding DUI Scientific Evidence*, 2013 Edition, Thomson Reuters/Aspatore.

ABSTRACTS:

1. "Pharmacokinetics of the Antineoplastic Agent Sodium Bromebrate (NSC 104801) in a Patient." A. E. Staubus, J. A. Neidhart, S. P. Balcerzak, M. S. Bathala and L. Malspeis, Acad. Pharm. Sci., 6, No. 2, 108 (1976).
2. "Quantitative Determination of Bromebric Acid (NSC 104801) as the Perfluorobenzyl Esters by Electron Capture." M. S. Bathala, A. E. Staubus and L. Malspeis, Acad. Pharm. Sci., 6, 108 (1976).
3. "Clinical Pharmacology of Sodium Bromebrate (NSC 104801) Cytembena." J. A. Neidhart, A. E. Staubus, W. S. Chow, S. P. Balcerzak and L. Malspeis, Proc. Am. Assoc. Cancer Res. 18, 92 (1977).
4. "Pharmacokinetics of m-AMSA (NSC 249992) in Humans." A. Staubus, J. Neidhart, D. Young and L. Malspeis, Proc. Am. Assoc. Cancer Res. 21, 198 (1980).
5. "Pharmacokinetics of Adriamycin in Man." W. S. Chow, L. Malspeis, A. E. Staubus and S. P. Balcerzak, Acad. Pharm. Sci., 10, No. 1, 83 (1980).
6. "HPLC Analysis of 1,4-Dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)-9,10-anthracenedione (NSC 279836) in Biological Samples and Preliminary Pharmacokinetic Studies in Dog." S. R. Cox, A. E. Staubus and L. Malspeis, Acad. Pharm. Sci., 10, No. 1, 77 (1980).
7. "Comparative Pharmacokinetics of 1,4-Dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)-9,10-anthracenedione (DHAD) in Beagles and Humans." S. R. Cox, A. E. Staubus, J. Neidhart and L. Malspeis, Acad. Pharm. Sci., 10, No. 2, 80 (1980).
8. "Pharmacokinetic Studies of Dihydroxyanthracenedione (DHAD, NSC 301739) with Clinical Correlations." J. Neidhart, A. Staubus, D. Young and L. Malspeis, Proc. Am. Soc. Clini. Oncol. 22, 363 (1981).
9. "HPLC Determination of Aclacinomycin A (NSC 208734, ACM) in Plasma and Application to Preliminary Pharmacokinetic Studies." L. Malspeis, J. Neidhart, A. Staubus, T. Kear and J. Booth, Proc. Am. Assoc. Cancer Res., 22, 242 (1981).
10. "An Enzymatic Kinetic Method for the Quantitation of 2'-Deoxycofomycin (2'-DCF, NSC 218321) in Biological Fluids." A. B. Weinrib, A. E. Staubus and L. Malspeis, Acad. Pharm. Sci., 11, No. 2, 133 (1981).

11. "Clinical Pharmacokinetics of Aclacinomycin A (NSC 208734, ACM)." L. Malspeis, David J. Gannaway, Alfred E. Staubus and James A. Neidhart, Proc. 13th Int. Cancer Congr., Seattle, Sept., 1982, p. 408.
12. "HPLC Analysis of 5,6-Dihydro-5-azacytidine (NSC 264880, DHAC) in Biological Fluids." L. Malspeis, Hai-Yung Cheng, H. B. Bhat and Alfred E. Staubus, Proc. 13th Int. Cancer Congr., Seattle, Sept., 1982, p. 554.
13. "Preliminary Pharmacokinetics of 5,6-Dihydro-5-azacytidine (NSC 264880, DHAC) in the Dog." L. Malspeis, Hai-Yung Cheng, H. B. Bhat and Alfred E. Staubus, Proc. 13th Int. Cancer Congr., Seattle, Sept., 1982, p. 554.
14. "Disposition and Metabolism Studies of 2- β -D-Ribofuranosyl-thiazole- 4-carboxamide (NSC 286193) in the Dog." J. J. V. Desouza, L. Malspeis, and A. E. Staubus. Acad. Pharm. Sci., 12, No. 2, 171 (1982).
15. "Concept of Time-Averaged Total Clearance and Mean Residence Time in Michaelis-Menten Elimination System." A. E. Staubus and D. F. Smith, APhA Academy of Pharmaceutical Sciences, 129th APhA Annual Meeting, April 24-29, 1982, Las Vegas, Nev., Vol. 12, No. 1.
16. "Tmax Analysis of First Moment Curves." Doug F. Smith and Alfred E. Staubus, American Pharmaceutical Association, Academy of Pharmaceutical Sciences 33rd National Meeting, San Diego, California, Nov. 14-18, 1982, p. 21.
17. "A Phase I Clinical Investigation of 5,6-Dihydro-5-azacytidine." M. R. Grever, J. A. Neidhart, D. Derocher, A. E. Staubus and L. Malspeis. Proc. Am. Soc. Clin. Oncol. 2, 38 (1983).
18. "Tiazofurin Pharmacokinetics in Dogs." Louis Malspeis, J. J. V. Desouza and Alfred E. Staubus. Proc. Am. Assoc. Cancer Res., 24, 288 (1983).
19. "Disposition and Metabolism of Tiazofurin (NSC 286193) in the Rat." Alfred E. Staubus, J. J. V. DeSouza and Louis Malspeis. Proc. Am. Assoc. Cancer Res., 24, 288 (1983).
20. "Plasma Pharmacokinetics of Mitoxantrone in Pediatric Patients." James S. Miser, Louis Malspeis, Alfred E. Staubus, Roger T. Guest, and James A. Neidhart. Proc. Am. Assoc. Cancer Res., 24, 132 (1983).

21. "Pharmacokinetics of 2-F-ARA-AMP in Man During a Phase I Clinical Trial." Malspeis, L., DeSouza, J. J. V., Staubus, A. E., Neidhart, J. A. and Grever, M. R. Fourth NCI-EORTC Symposium on New Drugs in Cancer Therapy, Brussels, Belgium. Investigational New Drugs, 2, 116 (1984).
22. "Clinical Pharmacokinetics of Amsacrine." Malspeis, L., Staubus, A. E., DeSouza, J. J. V. and Neidhart, J. A. Fourth NCI-EORTC Symposium on New Drugs in Cancer Therapy, Brussels, Belgium. Investigational New Drugs, 2, 110 (1984).
23. "Tiazofurin Pharmacokinetics During a Phase I Clinical Trial." L. Malspeis, J. A. Neidhart, A. E. Staubus, J. J. V. DeSouza, B. K. Dallaire and A. J. Grillo-Lopez. Proc. Am. Assoc. Cancer Res., 25, 163 (1984).
24. "Comparative Pharmacokinetics and Metabolism of Fludarabine Phosphate (NSC 312887) in Man and Dog." J. J. V. DeSouza, M. Grever, J. A. Neidhart, A. E. Staubus and L. Malspeis. Proc. Am. Assoc. Cancer Res., 25, 361 (1984).
25. "Renal Function Correlation with Total Body Plasma Clearance of 2-F-ARA-A Following Fludarabine Phosphate Administration in Man." A. E. Staubus, L. Malspeis, M. Grever, J. J. V. DeSouza and D. Young. APhA Acad. of Pharm. Sci., 14, No. 2, 183, (1984).
26. "Altered Pharmacokinetics of Fludarabine Phosphate (F) by 2'-Deoxycofomycin (DCF) in the Dog and Analysis of a Route of Fludarabine Activation." J. J. V. DeSouza, J. M. Leiby, A. E. Staubus, M. R. Grever and L. Malspeis. Proc. Am. Assoc. Cancer Res., 26, 358 (1985).
27. "Clinical Pharmacokinetics of Acodazole Hydrochloride (NSC 305884)." A. E. Staubus, J. J. V. DeSouza, M. R. Grever, J. A. Neidhart and L. Malspeis. Proc. Am. Assoc. Cancer Res., 26, 160 (1985).
28. "Disposition of 8-Methoxypsoralen in the Rat: Methodology for Measurement, Dose-Dependent Pharmacokinetics, Tissue Distribution and Identification of Metabolites." Dennis C. Mays, Sharon L. Rogers, Robert C. Guiler, Dale E. Sharp, Stephen G. Hecht, Alfred E. Staubus and Nicholas Gerber. J. Pharm. and Exp. Ther., 236, No. 2, 364-373 (1986).
29. "Comparison of the Clinical Pharmacokinetics of Acodazole Hydrochloride (NSC 305884) on Three Schedules During Phase I Trials." A. E. Staubus, J. J. V. DeSouza, M. R. Grever and L. Malspeis. Proc. Am. Assoc. Cancer Res., 27, 168 (1986).

30. "Pharmacokinetics and Metabolism of Nafidimide (NSC 308847) in Patients Following Single IV Bolus Administration." L. Malspeis, M. A. Salam, A. E. Staubus, M. E. Lyon, M. R. Grever, S. P. Balcerzak and J. M. Leiby. Proc. Am. Assoc. Cancer Res., 27, 169 (1986).
31. "Benzisoquinolinedione: A Clinical Phase I Study." J. M. Leiby, A. E. Staubus, L. Malspeis, M. R. Grever. Proc. Am. Assoc. Cancer Res., 27, 249 (1986).
32. "Preclinical Pharmacology Studies of Merbarone (NSC 336628)." L. Malspeis, M. E. Lyon, J. J. V. DeSouza and A. E. Staubus. Proc. Am. Assoc. Cancer Res., 27, 402 (1986).
33. "Potential Contribution of Petroleum Distillates to Apparent Alcohol Levels." Alfred E. Staubus. Presented at the American Academy of Forensic Sciences Meeting, New Orleans, LA, February 14, 1986.
34. "Development of a Rat Model for the Treatment of Glioblastoma by Boron Neutron Capture Therapy (BNCT)." R. F. Barth, N. R. Clendenon, J. R. Girvin, J. H. Goodman, A. E. Staubus, F. Alam, A. H. Soloway, T. E. Blue, T. C. Roberts, R. Gahbauer, C. Kanellitsas, R. E. Stephens, C. P. Boesel, A. J. Yates, M. J. Moeschberger, W. E. Hunt, W. E. Carey, J. Talngagi. Presented at the 14th International Cancer Congress, Budapest, Hungary, August 21-27, 1986.
35. "Pharmacokinetics and Metabolism of Inhaled Radiolabeled Tixocortol Pivalate." G. L. Fisher, A. E. Chin, B. A. Prentice, A. T. Mosberg, A. E. Staubus and W. E. Barrett. Presented at the International Society For Aerosols in Medicine, Vichy, France, October 2, 1986.
36. "Distribution of [2-14C]-Flavone Acetic Acid in Mice by Whole-Body Autoradiography." Louis Malspeis, Brian Kemmenoe and Alfred E. Staubus. Proc. Am. Assoc. Cancer Res., 28, 436, (1987).
37. "Dose-Dependent Pharmacokinetics of Flavone Acetic Acid (NSC 347512) in Humans." A. E. Staubus, M. E. Lyon, M. R. Grever, H. E. Wilson, Jr. and L. Malspeis. Proc. Am. Assoc. Cancer Res., 28, 227, (1987).
38. "Pharmacokinetics and Metabolism of Merbarone (NSC 336628) in Patients." L. Malspeis, A. E. Staubus, J. G. Supko, M. R. Grever and E. H. Kraut. Proc. Am. Assoc. Cancer Res., 28, 228, (1987).
39. "Dose-Dependent Pharmacokinetics of Flavone Acetic Acid (NSC 347512) in Dogs and Mice." L. Malspeis, A. E. Staubus, M. E. Lyon, B. Kemmenoe and D. S. Zaharko. Proc. Am. Assoc. Cancer Res., 29, 505, (1988).

40. "Plasma Protein Binding of Flavone Acetic Acid (NSC 347512, FAA) During Continuous Intravenous Infusion to Cancer Patients." A. E. Staubus, M. R. Grever, and L. Malspeis. Proc. Am. Assoc. Cancer Res., 29, 188, (1988).
41. "Spectral Characterization and Quantitation of the Principal Metabolites of Merbarone (NSC 336628) in the Urine of Patients." J. G. Supko, M. R. Grever, S. P. Balcerzak, E. H. Kraut, A. E. Staubus and L. Malspeis. Proc. Am. Assoc. Cancer Res., 29, 189, (1988).
42. "Amonafide (NSC 308847): A Clinical Phase I Study of Two Schedules of Administration." J. M. Leiby, L. Malspeis, A. E. Staubus, E. H. Kraut, and M. R. Grever. Proc. Am. Assoc. Cancer Res., 29, 178, (1988).
43. "Limited Sampling Models for Amonafide Pharmacokinetics." M. J. Ratain, A. E. Staubus, R. L. Schilsky, and L. Malspeis. Proc. Am. Assoc. Cancer Res., 29, 193, (1988).
44. "Merbarone (NSC 336628) Enhances the Urinary Excretion of Uric Acid in Cancer Patients." MR Grever, EH Kraut, JG Supko, RW Trewyn, AE Staubus, and L. Malspeis. Proc. Am. Assoc. Cancer Res., 29, 189, (1988).
45. "Phase I Clinical Trial of Merbarone (NSC 336628)." E. H. Kraut, M. R. Grever, A. E. Staubus, and L. Malspeis. Proc. Am. Assoc. Cancer Res., 29, 191, (1988).
46. "In Vitro and In Vivo Immunologic Effects of Flavone Acetic Acid in Man." J. Rinehart, A. Staubus, L. Malspeis, and M. Grever. Proc. Am. Assoc. Cancer Res., 29, 399, (1988).
47. "A Phase I Investigation of Flavone Acetic Acid (NSC 347512)." M. R. Grever, J. M. Leiby, E. H. Kraut, S. P. Balcerzak, A. E. Staubus and L. Malspeis. Proc. Am. Soc. Clin. Oncol., 7, 62 (1988).
48. "Fazarabine (NSC 281272) is Myelosuppressive at the Initial Dose Level in a Phase I Study." J. M. Leiby, L. Malspeis, A. E. Staubus, E. H. Kraut, and M. R. Grever. Proc. Am. Soc. Clin. Oncol., 7, 62 (1988).
49. "Oral Bioavailability of Merbarone (NSC 336628) in Dogs." A. E. Staubus, L. Malspeis, J. G. Supko, P. Snuffer and D. S. Zaharko. Proc. Am. Assoc. Cancer Res., 30, 533 (1989).
50. "Oral Bioavailability of 2-F-ara-A from Fludarabine Phosphate Capsules in Dogs." L. Malspeis, A. E. Staubus, M. E. Lyon, C. A. Gloff, and D. K. Tessman. Proc. Am. Assoc. Cancer Res., 30, 534 (1989).

51. "Dose Dependent Tissue Uptake of Flavone Acetic Acid, (NSC 347512, FAA), in mice." L. Malspeis, A. E. Staubus, B. H. Kemmenoe and D. S. Zaharko. Proc. Am. Assoc. Cancer Res., 30, 534 (1989).
52. "Clinical Pharmacokinetics of Fazarabine (NSC 281272)." Staubus, A. E., Malspeis, L., Balcerzak, S. P., Leiby, J. M., Kraut, E. H., and Grever, M. R. Proc. Am. Assoc. Cancer Res., 31, 177 (1990).
53. "Correlation of N-acetylation Phenotype with Plasma Levels of the N-acetyl Metabolite of Amonafide (NSC 308847)." Grever, M. R., Staubus, A. E. and Malspeis, L. Proc. Am. Assoc. Cancer Res., 31, 178 (1990).
54. "Direct Intratumoral Injection of 2'-O-(o-Carboran-1-ylmethyl Uridine (CBU-2')), a Potential Delivery Agent for Boron Neutron Capture Therapy (BNCT)." Nishihara, K., Barth, R.F., Liu, L., Tjarks, W., Soloway, A.H., Staubus, A.E., Rotaru, J., Adams, D.M., Bendayan, M. and Kassis, A. Proc. Am. Assoc. Cancer Res., 33, 502 (1992).
55. "Treatment of Intracerebral Melanoma by Means of Boron Neutron Capture Therapy (BNCT)." Matalka, K., Barth, R.F., Bailey, M.Q., Coderre, J.A., Staubus, A.E., Soloway, A.H., Carpenter, D.E., Adams, D.M., Goodman, J.H. and Rofstad, E.K. Proc. Am. Assoc. Cancer Res., 33, 503 (1992).
56. "Pharmacokinetics of Mitomycin C (MMC) During Intraperitoneal Hyperthermic Perfusion (IPHP)." Schneebaum, S., Staubus, A.E., Asif, M., Arnold, M. and Martin, E.W. Proc. Am. Assoc. Cancer Res., 33, 530 (1992).
57. "Kinetics of Ring Opening of Camptothecin (C) Analogs and Topotecan (T) in Plasma and Whole Blood." Staubus, A.E., Rutherford, M., Snuffer, P. and Feller, D. Proc. Am. Assoc. Cancer Res., 33, 531 (1992).
58. "A Phase I Study of Cyclosporin A with Ara-C, Mitoxantrone, Etoposide in Relapsed AML." Thornton, D.E., Villasmil, P., Staubus, A., Asif, M. and Balcerzak, S.P. Proc. Am. Assoc. Cancer Res., 35, 225 (1994).
59. "Pharmacokinetics of intracerebrally (i.c.) administered epidermal growth factor (EGF) in normal and glioma bearing rats." Capala, J., Barth, R.F., Tsai, J., Bailey, M.Q., Staubus, A.E. and Fenstermaker, R.A. Pro. Am. Assoc. Cancer Res., 35, 380 (1994).\

60. "Boron neutron capture therapy (BNCT) of a rat glioma." Barth, R.F., Rotaru, J., Staubus, A., Soloway, A.H. and Coderre, J. Pro. Am. Assoc. Cancer Res., 35, 637 (1994).
61. "Experimental Evidence for the Hixson-Crowell Cube Root Law Using a Single Spherical Particle", Belloto, R.J. and Staubus, A.E. AAPS Midyear Meeting (1996).
62. "False high Breath Alcohol Readings Due to Gastric Reflux", Staubus, A.E. American Academy of Forensic Sciences, Orlando, FL (February 15-19, 1999).
63. "A Statistical Analysis of Urine:Blood Data, and Oxycodone Redistribution: A Simple Ratio Will Not Suffice", Belloto, R.J. and Staubus, A.E. American Academy of Forensic Sciences, Chicago, IL (February 21-25, 2011).
64. "On the Statistical Distribution of Vmax for Ethanol Pharmacokinetics", Belloto R.J. and Staubus, A.E. American Academy of Forensic Sciences, New Orleans, LA (February 13-17, 2017).
65. "Potential Miscarriage of Justice Due to Hierarchical Error Messages for Ethanol Breath Testing", Staubus, A.E. and Belloto, R.J. International Association of Forensic Sciences, Toronto, Canada (August 21-25, 2017).
66. "Post-Mortem Drug Level Interpretation Using Pharmacokinetics and Statistics", Belloto, R.J. and Staubus, A.E. International Association of Forensic Sciences, Toronto, Canada (August 21-25, 2017).

A FEW EXAMPLES OF INVITED PRESENTATIONS:

1. "Current Trends - - The BAC DataMaster in Court" to OSU Police Department, Columbus, Ohio (October 21, 1997).
2. "Alcohol and Drug Testing" at the DUI Seminar for the Columbus Bar Association, Columbus, Ohio (November 12, 1997).
3. "Powerful Analogies, Techniques, Anecdotes, Similes, Metaphors, 'Segue Ways', and other Tools That Help Explain Science to Jurors or Judges" at the 8th Annual Mastering Scientific Evidence in DUI/DWI Cases, Atlanta, GA (April 5-7, 2001).
4. "Toxicology", A Day in the Life of a Criminal Defense Lawyer, The Texas Criminal Defense Lawyers Project, Port Aransas, Texas (January 23, 2004).

5. "Drug Testing In The State of Ohio" and "Alcohol Testing In The State of Ohio", at the Lorman Education Services' "Traffic Law Practices and Impaired Driving Law Issues In Ohio", Cincinnati, OH (May 21, 2004).
6. "Forensic Drug Testing" at the 10th Annual Summer Session of the National College for DUI Defense (NCDD), Harvard Law School (July 21-24, 2004).
7. "Intoxilyzer 5000 & 8000 Infrared (IR) Basics and "The Widmark Equation" at the Intoxilyzer 5000 & 8000 Breath Testing Training Course, Atlanta, GA (April 8, 2005).
8. "Intoxilyzer 8000 - - Machine Qualifications" at the Mississippi intoxilyzer 8000 "What Tennessee Knows that the Rest of Us Do Not", Jackson, MS (April 8, 2005).
9. "Advance DUI Seminar" at the Ohio Association of Criminal Defense Lawyers, Columbus, Ohio (March 2-3, 2006).
10. "OVI Issues From the Defense Perspective" at the 2006 OPAA Spring Training Seminar, the Ohio prosecuting Attorneys Association, Columbus, Ohio (March 24, 2006).
11. "The Intoxilyzer 8000" at the Mississippi Justice Court Judges Association 2007 Summer Convention, Biloxi, MS (July 9, 2007).
12. "Intoxication by Drug – Vastly Different than Alcohol" at the 2013 Mastering Scientific Evidence Seminar, the NCDD and the TCDLA, New Orleans, LA (March 22, 2013).
13. "SFSTs: Why Age and Weight Produce False Results" at the Michigan Judicial Symposium, Michigan Hall of Justice, Lansing, MI (May 6, 2015).
14. "SFSTs: Why Age and Weight Produce False Results" at the Michigan District Judges Association (MDJA) Judicial Conference, Thompsonville, MI (August 17, 2015).
15. "Proper Pharmacological Evaluation in the Workplace of Blood and Urine Levels of Alcohol and Other Drugs and Their Metabolites" at the Fall 2017 Ohio Industrial Commission Statewide Hearing Officer Meeting, Columbus, OH (September 11, 2017).